Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.480 +0.070 (+1.59%)
Streaming Delayed Price Updated: 11:22 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 Next >
Arbutus Biopharma: Q1 Earnings Insights
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
Arbutus Biopharma Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter... 
Via Benzinga
Arbutus Biopharma: Q4 Earnings Insights
Arbutus Biopharma (NASDAQ:ABUS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for infringing on their patent on a lipid... 
Via Benzinga
Futures, Global Markets Soar In Biggest 4-Day Rally Since November 2020
US equity futures and global stocks from Europe to Asia were headed for the biggest four-day rally since November 2020, supercharged by blockbuster earnings AMD and Google, which hit an all time high... 
Via Talk Markets
23 Stocks Moving in Wednesday's Pre-Market Session
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're ready for another busy week of trading as we start it with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
25 Stocks Moving in Monday's Pre-Market Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to the Russell 2000 Index. Verso Corporation (NYSE:... 
Via Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022
Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off? 
Via Investor's Business Daily
Why Arbutus Biopharma Shares Are Rising
Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia... 
Via Benzinga
Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact
Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating... 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)... 
Via Benzinga
Why Moderna Stock Plunged Today
A patent dispute could pressure the vaccine maker's profits. 
Via The Motley Fool
Topics Intellectual Property
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 0.39% to 34,617.2 while the NASDAQ climbed 0.17% to 15,564.73. The S&P also rose, gaining 0.68% to 4,597.96. The U.S.... 
Via Benzinga
Topics Stocks
Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor... 
Via Benzinga
ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today
Arbutus Biopharma (ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (MRNA). 
Via InvestorPlace
Topics Intellectual Property
Why Arbutus Shares Are Soaring Today
Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to... 
Via Benzinga
Topics Intellectual Property
Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide
Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64. The U.S. has... 
Via Benzinga
Topics Stocks
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.